Effect of standard nicotinamide in the prevention of type 1 diabetes in first degree relatives of persons with type 1 diabetes

Autor:	M. Prieto, Umberto Di Mario, Oscar Diaz-Horta, Dania Chiong, Emma Domínguez, Antonio Gutierrez, Rafael León, Amparo Govea, Olga María Rodríguez, José Manuel Hernández, Tamara Fernández, Gisela Molina, Saúl Padrón, Manuel Vera, Juana Tillan, Igrid García, Eduardo Cabrera-Rode, Celeste Arranz, Rolando Suárez, Oscar Díaz-Díaz, Claudio Tiberti, Pedro Gonzalez
Rok vydání:	2006
Předmět:	Adult Blood Glucose Male Niacinamide medicine.medical_specialty Adolescent medicine.medical_treatment Immunology law.invention Prediabetic State chemistry.chemical_compound Double-Blind Method Randomized controlled trial law Internal medicine Diabetes mellitus Insulin Secretion Humans Insulin Immunology and Allergy Medicine Genetic Predisposition to Disease First-degree relatives Child Autoantibodies Type 1 diabetes Glucose tolerance test Nicotinamide medicine.diagnostic_test business.industry HLA-DR Antigens Glucose Tolerance Test medicine.disease B vitamins Diabetes Mellitus Type 1 Endocrinology chemistry Child Preschool Vitamin B Complex Female business
Zdroj:	Autoimmunity. 39:333-340
ISSN:	1607-842X 0891-6934
DOI:	10.1080/08916930600738383
Popis:	Nicotinamide has been used with success to prevent type 1 diabetes in animal models and humans. This vitamin B3 derivative has attracting effects on beta-cell protection and regeneration.To evaluate the effect of standard nicotinamide administration on type 1 diabetes prevention in first degree relatives of persons with type 1 diabetes as well as on the concentrations of islet-cell-related autoantibodies, insulin secretion and peripheral sensitivity.A randomized double-blind placebo controlled intervention trial was conducted in 40 first degree relatives of type 1 diabetic patients. Persistence of ICA (or= 10 JDF units) was among inclusion criteria. Participants were randomly allocated oral standard nicotinamide (1.2 g/m2) or placebo for 5 years. Groups were also stratified by age. Islet associated antibodies, fasting blood glucose, fasting plasma insulin concentrations, OGTT, IVGTT and HLA-DR genotyping were performed in all participants. The main criterion to stop treatment was type 1 diabetes development as defined by WHO.Type 1 diabetes development frequencies were similar between the treatment groups. ICA frequencies at the end of the study, first phase insulin release, and insulin sensitivity did not differ between groups as well. None of the participants suffered from any adverse events described for nicotinamide.Type 1 diabetes prevention trial using standard nicotinamide is feasible but fails to prevent or delay the disease onset at the dose we used.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df06c44e4a220f35a80202fac5420776 https://doi.org/10.1080/08916930600738383 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.